Regenexx announced it merged with Harbor View Medical, which became effective in May 2017. As part of the transition, Jason Hellickson has assumed the CEO role.
Regenexx Corporate will be headquartered in Des Moines, IA, while Regenexx’s Affiliate Program and Research and Development will be lead out of the company’s Broomfield, CO location. Dr. Christopher Centeno, founder of orthopedic stem cell treatments and leader of interventional orthopedics in the United States and pioneer of the Regenexx patented procedures, will continue his role as Chief Medical Officer and remain in clinic operations in Broomfield, and continues the advancements of regenerative medicine through the largest research and data collection effort in orthopedic regenerative medicine.
“As the most advanced non-surgical orthopedic care available in the United States, I’m excited to continue our mission to producing the best possible patient outcomes through interventional orthopedics,” said Jason Hellickson, CEO, Regenexx. “In addition to individual personalized care, we will continue to provide both employers and their employees with cost savings results and successful interventions to orthopedic surgery.”
Since joining the Regenexx Network in late 2014, Hellickson has reengineered clinic operations which increased capacity by more than 300 percent while offering a streamlined approach beneficial to both patients and clinic staff. He is the innovator and leader of the Regenexx Corporate Program that enables large employers access to the Regenexx procedures. Since adding Regenexx procedures to their self-funded health and workers’ compensation plans, corporate partners have saved as much as 83 percent in their orthopedic surgical expenses, totaling in the many millions of dollars. In his new role, Hellickson will continue to architect the Regenexx national clinical operations to create more streamlined approaches to patient care and expand Regenexx clinics nationwide.
Regenexx focuses on interventional orthopedics using orthobiologics and has been issued many patents for its evidence-based stem cell and blood platelet treatments used for back pain, joint pain, arthritis and acute orthopedic injuries. Mesenchymal stem cells are multipotent, adult stem cells that are therapeutic agents in the repair and regeneration of muscle, tissue, cartilage and bone. Regenexx procedures use a patient’s own bone marrow-derived stem cells, or blood platelets, through a blood draw, to customize needle-based, precisely-guided procedures to treat common orthopedic conditions. Its procedures have been proven to have the same or better outcomes compared to their surgical alternative.